Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: August 13, 2025
Business Overview: BioCardia is a global leader in cellular and cell-directed therapeutics for cardiovascular and pulmonary diseases. The company is listed on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The primary material event reported is the execution of an exclusive development and commercialization agreement between BioCardia, Inc. and CART-Tech, B.V. on August 13, 2025. The agreement concerns the Heart3D Fusion Imaging system. This technology is designed to enhance two-dimensional x-ray images used in cardiac biotherapeutic delivery and biopsy procedures by fusing them with annotated pre-procedure three-dimensional anatomical heart models derived from MRI and CT images.
Guidance, Outlook, and Management Commentary
- Strategic Outlook: The partnership aims to improve imaging capabilities for cardiac interventions through vendor-independent platform technology for augmented fluoroscopy.
- Management Commentary: The filing references a joint press release (Exhibit 99.1) but does not include direct quotes or detailed management commentary within the text of the 8-K itself.
- Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in this filing text beyond the standard nature of entering into a new commercial agreement.
Investor Verification Checklist
- Review the full text of the joint press release attached as Exhibit 99.1 for specific terms of the agreement with CART-Tech, B.V.
- Verify the commercialization timeline and revenue recognition implications of the Heart3D Fusion Imaging agreement.
- Assess the integration plan for the Heart3D system with BioCardia's existing biotherapeutic delivery procedures.
- Confirm the financial impact of this agreement on future quarters, as no immediate financial data is provided in this report.